{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:13:05Z","timestamp":1771668785497,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurophysiologie Clinique\/Clinical Neurophysiology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.neucli.2006.12.003","type":"journal-article","created":{"date-parts":[[2007,1,26]],"date-time":"2007-01-26T17:44:42Z","timestamp":1169833482000},"page":"333-336","source":"Crossref","is-referenced-by-count":37,"title":["Drug-induced myoclonus: a\u00a0French pharmacovigilance database study"],"prefix":"10.1016","volume":"36","author":[{"given":"C.","family":"Brefel-Courbon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gardette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neucli.2006.12.003_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0013-4694(94)00268-P","article-title":"Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin","volume":"94","author":"Aguglia","year":"1995","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.neucli.2006.12.003_bib2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1528-1157.2000.tb00192.x","article-title":"Myoclonus associated with the use of gabapentin","volume":"41","author":"Asconape","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neucli.2006.12.003_bib3","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"Begaud","year":"1985","journal-title":"Therapie"},{"key":"10.1016\/j.neucli.2006.12.003_bib4","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"Begaud","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.neucli.2006.12.003_bib5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/mds.870110318","article-title":"Complex movement disorders induced by fluoxetine","volume":"11","author":"Bharucha","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neucli.2006.12.003_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.wnf.0000165351.10841.fa","article-title":"Olanzapine-induced myoclonic status","volume":"28","author":"Camacho","year":"2005","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neucli.2006.12.003_bib7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.neucli.2006.12.003_bib8","first-page":"5551","article-title":"Food and Drug Administration, HHS International Conference on Harmonisation; guidance on Addendum to E2C Clinical Safety Data Management: periodic safety update reports for marketed drugs","volume":"69","year":"2004","journal-title":"Fed Regist."},{"issue":"27","key":"10.1016\/j.neucli.2006.12.003_bib9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/0006-3223(90)90048-7","article-title":"Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients","volume":"15","author":"Fukuzako","year":"1990","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neucli.2006.12.003_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/archpsyc.1987.01800150081010","article-title":"Occurrence of myoclonus in patients treated with cyclic antidepressants","volume":"44","author":"Garvey","year":"1987","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neucli.2006.12.003_bib11","series-title":"Myoclonus and paroxysmal dyskinesias, advances in neurology","first-page":"49","article-title":"Toxin and drug-induced myoclonus","author":"Gordon","year":"2002"},{"key":"10.1016\/j.neucli.2006.12.003_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00023210-200418020-00003","article-title":"Drug-induced myoclonus: frequency, mechanisms and management","volume":"18","author":"Jimenez-Jimenez","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neucli.2006.12.003_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archneur.1975.00490470075011","article-title":"Levodopa-induced myoclonus","volume":"32","author":"Klawans","year":"1975","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neucli.2006.12.003_bib14","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/jnnp.51.7.1002-a","article-title":"Acute dystonic reaction with asterixis and myoclonus following metoclopramide therapy","volume":"51","author":"Lu","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neucli.2006.12.003_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.870070204","article-title":"Levodopa-induced dyskinesias in Parkinson\u2019s disease: clinical and pharmacological classification","volume":"7","author":"Luquin","year":"1992","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neucli.2006.12.003_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.870090103","article-title":"Levodopa-induced dyskinesias in Parkinson\u2019s disease phenomenology and pathophysiology","volume":"9","author":"Marconi","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neucli.2006.12.003_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00005792-200007000-00001","article-title":"Serotonin syndrome. Presentation of 2 cases and review of the literature","volume":"79","author":"Mason","year":"2000","journal-title":"Medicine"},{"issue":"56","key":"10.1016\/j.neucli.2006.12.003_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/WNL.56.2.279","article-title":"Amantadine-induced cortical myoclonus","volume":"23","author":"Matsunaga","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neucli.2006.12.003_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00002826-198205020-00003","article-title":"Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis","volume":"5","author":"Nausieda","year":"1982","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neucli.2006.12.003_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000050749","article-title":"Switch-over from tolcapone to entacapone in severe Parkinson\u2019s disease patients","volume":"46","author":"Onofrj","year":"2001","journal-title":"Eur. Neurol."},{"issue":"39","key":"10.1016\/j.neucli.2006.12.003_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0006-3223(95)00499-8","article-title":"Clozapine-induced myoclonus and generalized seizures","volume":"1","author":"Sajatovic","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neucli.2006.12.003_bib22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mds.870130606","article-title":"A community-based study of sleep disorders in patients with Parkinson\u2019s disease","volume":"13","author":"Tandberg","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neucli.2006.12.003_bib23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00002018-200528080-00007","article-title":"Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986\u20132001)","volume":"28","author":"Thiessard","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.neucli.2006.12.003_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00314716","article-title":"Myoclonic attacks induced by l-dopa and bromocryptin in Parkinson patients: a sleep EEG study","volume":"218","author":"Vardi","year":"1978","journal-title":"J. Neurol."},{"key":"10.1016\/j.neucli.2006.12.003_bib25","first-page":"19","article-title":"Definitions-serious, severe reactions","volume":"23","year":"1993","journal-title":"OMS Report"}],"container-title":["Neurophysiologie Clinique\/Clinical Neurophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0987705306001328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0987705306001328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T16:56:28Z","timestamp":1547052988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0987705306001328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":25,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0987705306001328"],"URL":"https:\/\/doi.org\/10.1016\/j.neucli.2006.12.003","relation":{},"ISSN":["0987-7053"],"issn-type":[{"value":"0987-7053","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}